Reports Q1 revenue $5.611M vs $5.035M last year. “We are pleased to report a solid start to 2024,” said Robert Spignesi, President and CEO. “First quarter revenues exceeded our guidance and we achieved a new record in consumable revenue in the period. We remain focused on accelerating Growth Direct system placements, improving gross margins and driving the business to profitability. We are reaffirming our full year 2024 total revenue guidance as we look forward to the mid-year launch of our innovative Growth Direct Rapid Sterility platform.”
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPID:
- Rapid Micro Biosystems Reports First Quarter 2024 Financial Results
- Is RPID a Buy, Before Earnings?
- Rapid Micro Biosystems to Announce First Quarter 2024 Financial Results on May 3, 2024
- Rapid Micro Biosystems to Exhibit at the 2024 PDA Annual Meeting from March 25 – 27, 2024
- Rapid Micro Biosystems to Participate in the Virtual KeyBanc Life Sciences & MedTech Investor Forum